ATE487719T1 - Xanthinderivate als selektive hm74a-agonisten - Google Patents

Xanthinderivate als selektive hm74a-agonisten

Info

Publication number
ATE487719T1
ATE487719T1 AT06763016T AT06763016T ATE487719T1 AT E487719 T1 ATE487719 T1 AT E487719T1 AT 06763016 T AT06763016 T AT 06763016T AT 06763016 T AT06763016 T AT 06763016T AT E487719 T1 ATE487719 T1 AT E487719T1
Authority
AT
Austria
Prior art keywords
xanthine derivatives
hm74a agonists
selective
selective hm74a
agonists
Prior art date
Application number
AT06763016T
Other languages
German (de)
English (en)
Inventor
Richard Hatley
Andrew Mason
Ivan PINTO
Original Assignee
Glaxosmithkline Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0516464A external-priority patent/GB0516464D0/en
Priority claimed from GB0607736A external-priority patent/GB0607736D0/en
Priority claimed from GB0614569A external-priority patent/GB0614569D0/en
Application filed by Glaxosmithkline Llc filed Critical Glaxosmithkline Llc
Application granted granted Critical
Publication of ATE487719T1 publication Critical patent/ATE487719T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Nutrition Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT06763016T 2005-08-10 2006-08-08 Xanthinderivate als selektive hm74a-agonisten ATE487719T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0516464A GB0516464D0 (en) 2005-08-10 2005-08-10 Novel compounds
GB0607736A GB0607736D0 (en) 2006-04-19 2006-04-19 Novel compounds
GB0614569A GB0614569D0 (en) 2006-07-21 2006-07-21 Novel compounds
PCT/EP2006/007865 WO2007017261A1 (en) 2005-08-10 2006-08-08 Xanthine derivatives as selective hm74a agonists

Publications (1)

Publication Number Publication Date
ATE487719T1 true ATE487719T1 (de) 2010-11-15

Family

ID=37189397

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06763016T ATE487719T1 (de) 2005-08-10 2006-08-08 Xanthinderivate als selektive hm74a-agonisten

Country Status (28)

Country Link
US (3) US20100179128A1 (OSRAM)
EP (3) EP2272848B1 (OSRAM)
JP (2) JP5112316B2 (OSRAM)
KR (2) KR20080038396A (OSRAM)
AR (1) AR055369A1 (OSRAM)
AT (1) ATE487719T1 (OSRAM)
AU (2) AU2006278216A1 (OSRAM)
BR (2) BRPI0615145A2 (OSRAM)
CA (2) CA2626723A1 (OSRAM)
CR (2) CR9748A (OSRAM)
CY (1) CY1111757T1 (OSRAM)
DE (1) DE602006018151D1 (OSRAM)
DK (1) DK1912991T3 (OSRAM)
EA (2) EA014556B1 (OSRAM)
ES (1) ES2401128T3 (OSRAM)
HR (1) HRP20100725T1 (OSRAM)
IL (2) IL189081A0 (OSRAM)
MA (2) MA29693B1 (OSRAM)
MX (2) MX2008001929A (OSRAM)
MY (1) MY142067A (OSRAM)
NO (2) NO20081211L (OSRAM)
NZ (1) NZ565494A (OSRAM)
PE (1) PE20070405A1 (OSRAM)
PL (1) PL1912991T3 (OSRAM)
PT (1) PT1912991E (OSRAM)
SI (1) SI1912991T1 (OSRAM)
TW (1) TW200800217A (OSRAM)
WO (2) WO2007017262A1 (OSRAM)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7495005B2 (en) * 2002-08-22 2009-02-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Xanthine derivatives, their preparation and their use in pharmaceutical compositions
PT1781657E (pt) * 2004-02-14 2013-05-23 Glaxosmithkline Ip Dev Ltd Medicamentos com actividade no receptor hm74a
DE102004030502A1 (de) 2004-06-24 2006-01-12 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Imidazole und Triazole, deren Herstellung und Verwendung als Arzneimittel
WO2007017262A1 (en) * 2005-08-10 2007-02-15 Smithkline Beecham Corporation Xanthine derivatives as selective hm74a agonists
AU2007260852B2 (en) 2006-06-23 2013-01-10 Incyte Corporation Purinone derivatives as HM74a agonists
CA2656039A1 (en) 2006-06-23 2007-12-27 Incyte Corporation Purinone derivatives as hm74a agonists
BRPI0715160A2 (pt) 2006-08-08 2013-06-11 Sanofi Aventis imidazolidina-2,4-dionas substituÍdas por arilamimoaril-alquil-, processo para preparÁ-las, medicamentos compeendendo estes compostos, e seu uso
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE102007054497B3 (de) 2007-11-13 2009-07-23 Sanofi-Aventis Deutschland Gmbh Neue kristalline Diphenylazetidinonhydrate und Verfahren zu deren Herstellung
WO2010003624A2 (en) 2008-07-09 2010-01-14 Sanofi-Aventis Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
JP5666464B2 (ja) 2008-12-08 2015-02-12 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーＧｌａｘｏＳｍｉｔｈＫｌｉｎｅ ＬＬＣ 新規化合物
ES2443016T3 (es) 2009-08-26 2014-02-17 Sanofi Nuevos hidratos cristalinos de fluoroglicósidos heteroaromáticos, productos farmacéuticos que comprenden estos compuestos, y su empleo
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
KR101799429B1 (ko) 2010-05-03 2017-11-21 에스케이바이오팜 주식회사 신경 세포 사멸 또는 신경 퇴화를 억제하기 위한 약학적 조성물
US8933024B2 (en) 2010-06-18 2015-01-13 Sanofi Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
CA2807364A1 (en) * 2010-08-16 2012-02-23 Boehringer Ingelheim International Gmbh Oxadiazole inhibitors of leukotriene production
US8580825B2 (en) * 2010-09-23 2013-11-12 Boehringer Ingelheim International Gmbh Oxadiazole inhibitors of leukotriene production
WO2012120053A1 (de) 2011-03-08 2012-09-13 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8828994B2 (en) 2011-03-08 2014-09-09 Sanofi Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
US8871758B2 (en) 2011-03-08 2014-10-28 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
EP2766349B1 (de) 2011-03-08 2016-06-01 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2012120055A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EA201492069A1 (ru) * 2012-05-30 2015-03-31 Ф.Хоффманн-Ля Рош Аг Соединения триазола в качестве ингибиторов фосфодиэстеразы 10 (pde10)
KR102227629B1 (ko) * 2013-03-15 2021-03-16 하이드라 바이오사이언시스, 엘엘씨 치환된 잔틴 및 그것의 사용 방법
JP6434498B2 (ja) 2013-05-10 2018-12-05 ギリアド アポロ， エルエルシー Ａｃｃ阻害剤及びその使用
HK1221420A1 (zh) 2013-05-10 2017-06-02 Gilead Apollo, Inc. Acc抑制剂和其用途
KR20160005364A (ko) 2013-05-10 2016-01-14 님버스 아폴로, 인코포레이티드 Acc 억제제 및 이의 용도
MX2015015417A (es) * 2013-05-10 2016-06-21 Nimbus Apollo Inc Inhibidores de acetil-coa carboxilasa (acc) y usos de los mismos.
CN105646492B (zh) * 2014-11-14 2019-04-09 中国医学科学院药物研究所 含五元芳杂环的取代黄嘌呤类化合物及其制备方法和用途
DE102017000359A1 (de) 2016-08-26 2018-03-01 Bihl+Wiedemann Gmbh Diagnose-Repeater für AS-Interface Netze
CN110461838B (zh) * 2017-03-07 2022-05-06 豪夫迈·罗氏有限公司 噁二唑瞬时受体电位通道抑制剂
CN112724141A (zh) * 2021-01-21 2021-04-30 南京艾美斐生物医药科技有限公司 一种gpr109a蛋白受体抑制剂及其制备和应用
CR20240352A (es) * 2022-02-03 2024-09-18 De Shaw Res Llc Compuestos de uracilo sustituidos por n3 como inhibidores de trpa1
EP4658262A1 (en) * 2023-01-30 2025-12-10 D.E. Shaw Research, LLC Bicyclic imide compounds as trpa1 inhibitors
AR133217A1 (es) * 2023-07-10 2025-09-10 De Shaw Res Llc Inhibidores de trpa1 bicíclicos y monocíclicos

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2797220A (en) 1954-12-02 1957-06-25 Univ Michigan Substituted paraxanthines
GB8906792D0 (en) 1989-03-23 1989-05-10 Beecham Wuelfing Gmbh & Co Kg Treatment and compounds
IL100088A (en) 1990-11-21 1995-07-31 Smithkline Beecham Corp FNT inhibitor preparations containing histogenic transducts converted at positions 1, 3, and 8
AU3725893A (en) 1992-02-21 1993-09-13 Smithkline Beecham Corporation TNF inhibitors
DE69332634T2 (de) 1992-03-04 2003-05-08 Cell Therapeutics, Inc. Enantiomere hydroxylierte xanthinverbindungen
US5473070A (en) 1992-11-16 1995-12-05 Cell Therapeutics, Inc. Substituted long chain alcohol xanthine compounds
US5780476A (en) 1992-11-16 1998-07-14 Cell Therapeutics, Inc. Hydroxyl-containing xanthine compounds
US6469017B1 (en) 1998-01-16 2002-10-22 Cell Therapeutics, Inc. Method of inhibiting interleukin-12 signaling
US6693105B1 (en) 1992-11-16 2004-02-17 Cell Therapeutics, Inc. Hydroxyl-containing compounds
IL109161A0 (en) 1993-03-31 1994-06-24 Cell Therapeutics Inc Amino alcohol derivatives, methods for the preparation thereof, and pharmaceutical compositions containing the same
US5670506A (en) 1993-04-05 1997-09-23 Cell Therapeutics, Inc. Halogen, isothiocyanate or azide substituted xanthines
AU6702894A (en) 1993-04-09 1994-11-08 Cell Therapeutics, Inc. Ring-substituted cell signaling inhibitors
AU1868195A (en) 1994-01-28 1995-08-15 Cell Therapeutics, Inc. Cell signaling inhibitors
US6780865B1 (en) 1994-02-18 2004-08-24 Cell Therapeutics, Inc. Compounds having selective hydrolytic potentials
AU1967495A (en) 1994-02-18 1995-09-04 Cell Therapeutics, Inc. Intracellular signalling mediators
US6103730A (en) 1994-03-24 2000-08-15 Cell Therapeutics, Inc. Amine substituted compounds
US6878715B1 (en) 1994-02-18 2005-04-12 Cell Therapeutics, Inc. Therapeutic compounds for inhibiting interleukin-12 signals and method for using same
US5807861A (en) 1994-03-24 1998-09-15 Cell Therapeutics, Inc. Amine substituted xanthinyl compounds
US6323201B1 (en) * 1994-12-29 2001-11-27 The Regents Of The University Of California Compounds for inhibition of ceramide-mediated signal transduction
AR015966A1 (es) 1997-10-17 2001-05-30 Smithkline Beecham Corp Uso de un compuesto inhibidor de pde4 para la preparacion de un medicamento util para el tratamiento de prurito
MXPA01010143A (es) 1999-04-09 2003-07-14 Cell Therapeutics Inc Derivados de xantina y analogos como inhibidores de transmision de senales celulares.
US20030207901A1 (en) 1999-07-27 2003-11-06 Cell Therapeutics, Inc. Hydroxyl-containing compounds
US6821978B2 (en) 2000-09-19 2004-11-23 Schering Corporation Xanthine phosphodiesterase V inhibitors
US6586429B2 (en) * 2000-11-29 2003-07-01 Cell Therapeutics, Inc. Tricyclic fused xanthine compounds and their uses
CZ305402B6 (cs) 2001-02-24 2015-09-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg Xanthinové deriváty, jejich výroba a použití v kombinační terapii
AU2002242910A1 (en) 2001-04-11 2002-10-28 Glaxo Group Limited Medicaments which are modulators of hm74 and/or hm74a activity
ATE388951T1 (de) * 2001-07-03 2008-03-15 Novo Nordisk As Dpp-iv-inhibierende purin-derivative zur behandlung von diabetes
EP1338595B1 (en) 2002-02-25 2006-05-03 Eisai Co., Ltd. Xanthine derivatives as DPP-IV inhibitors
US7482337B2 (en) 2002-11-08 2009-01-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions
CN1227492C (zh) * 2003-03-11 2005-11-16 张跃 一种吸收式空调主体
GB0319124D0 (en) * 2003-08-14 2003-09-17 Smithkline Beecham Corp Chemical compounds
PT1781657E (pt) 2004-02-14 2013-05-23 Glaxosmithkline Ip Dev Ltd Medicamentos com actividade no receptor hm74a
WO2006045564A1 (en) * 2004-10-22 2006-05-04 Smithkline Beecham Corporation Xanthine derivatives with hm74a receptor activity
AU2005298891A1 (en) * 2004-10-22 2006-05-04 Smithkline Beecham Corporation Xanthine derivatives with HM74A receptor activity
US20090209561A1 (en) * 2004-10-22 2009-08-20 Richard Jonathan Daniel Hatley Xanthine Derivatives with HM74A Receptor Activity
US20080221108A1 (en) 2005-02-14 2008-09-11 Richard Hatley Anthranilic Acid Derivatives As Hm74A Receptor Agonists
GB0516462D0 (en) * 2005-08-10 2005-09-14 Smithkline Beecham Corp Novel compounds
WO2007017262A1 (en) * 2005-08-10 2007-02-15 Smithkline Beecham Corporation Xanthine derivatives as selective hm74a agonists
DE102008009758A1 (de) * 2008-02-18 2009-08-20 Beiersdorf Ag Verwendung von 3-(4-Hydroxy-3-methoxyphenyl)-1-(4-hydroxyphenyl)-propan-1-on zur verbesserten Hautkonturierung bzw. gegen Cellulite
JP5666464B2 (ja) 2008-12-08 2015-02-12 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーＧｌａｘｏＳｍｉｔｈＫｌｉｎｅ ＬＬＣ 新規化合物

Also Published As

Publication number Publication date
IL189081A0 (en) 2008-08-07
PL1912991T3 (pl) 2011-04-29
MX2008001929A (es) 2008-03-24
EA014556B1 (ru) 2010-12-30
US8143264B2 (en) 2012-03-27
EA200800555A1 (ru) 2008-08-29
TW200800217A (en) 2008-01-01
WO2007017261A1 (en) 2007-02-15
HRP20100725T1 (hr) 2011-01-31
AU2006278215A1 (en) 2007-02-15
DE602006018151D1 (de) 2010-12-23
KR20080038396A (ko) 2008-05-06
MY142067A (en) 2010-08-30
MX2008001931A (es) 2008-03-24
PT1912991E (pt) 2011-01-17
ES2401128T3 (es) 2013-04-17
EP2272848B1 (en) 2012-12-26
EP1912991B1 (en) 2010-11-10
CR9749A (es) 2008-05-22
CR9748A (es) 2008-05-05
CY1111757T1 (el) 2015-10-07
HK1116779A1 (en) 2009-01-02
CA2618963A1 (en) 2007-02-15
PE20070405A1 (es) 2007-05-06
US20110257205A1 (en) 2011-10-20
DK1912991T3 (da) 2011-02-21
WO2007017262A1 (en) 2007-02-15
MA29693B1 (fr) 2008-08-01
KR20080034993A (ko) 2008-04-22
NZ565494A (en) 2011-06-30
AU2006278216A1 (en) 2007-02-15
NO20081212L (no) 2008-05-06
JP5112316B2 (ja) 2013-01-09
JP2009504592A (ja) 2009-02-05
JP2009504591A (ja) 2009-02-05
BRPI0615145A2 (pt) 2009-11-03
CA2626723A1 (en) 2007-02-15
US20100168122A1 (en) 2010-07-01
IL189083A0 (en) 2008-08-07
NO20081211L (no) 2008-05-08
US20100179128A1 (en) 2010-07-15
SI1912991T1 (sl) 2011-03-31
EA200800564A1 (ru) 2008-08-29
AR055369A1 (es) 2007-08-22
EP1912991A1 (en) 2008-04-23
EP1912992A1 (en) 2008-04-23
BRPI0614270A2 (pt) 2011-03-22
EP2272848A1 (en) 2011-01-12
MA29692B1 (fr) 2008-08-01

Similar Documents

Publication Publication Date Title
ATE487719T1 (de) Xanthinderivate als selektive hm74a-agonisten
ATE486874T1 (de) Purinonderivate als hm74a-agonisten
NL1031741A1 (nl) Purinederivaten.
NL2000323A1 (nl) Pyrimidine-derivaten.
DE602006015607D1 (de) Thiazol-4-carboxamid-derivate als mglur5-antagonisten
ATE518860T1 (de) Pyrroloä2,3-büpyridinderivate als proteinkinaseinhibitoren
NL2000371A1 (nl) Chromaan gesubstitueerde benzimidazoolderivaten.
ATE517886T1 (de) Pyrazolderivate
ATE434613T1 (de) Isochinolinderivate
IL195904A0 (en) Purinone derivatives as hm74a agonists
DE602006016566D1 (de) Als antikoagulanzien verwendbare phenylglycinamid-derivate
ATE414085T1 (de) Purinderivate als a2a-rezeptoragonisten
DE602006010508D1 (de) Substituierte triazolderivate als oxytocinantagonisten
NL2000284A1 (nl) Pyrazine-derivaten.
DE602006010581D1 (de) 4-phenyl-6-substituierte pyrimidin-2-carbonitrilderivate
ATE487718T1 (de) Substituierte bizyklische pyrimidonderivate
ATE435225T1 (de) Oxadiazolonderivate als ppar-delta-agonisten
ATE485294T1 (de) Azaindol-2-carboxamid-derivate
ATE527255T1 (de) Aryl-isoxazol-4-yl-imidazol-derivate
DK1971588T3 (da) Tiglien-3-onderivater
ZA200800778B (en) Xanthine derivatives as selective HM74A agonists
ATE435865T1 (de) Als pde5-inhibitoren verwendete pyrazoloä4,3- düpyrimidin-5-ylderivate
DE602006007832D1 (de) Benzotriazolderivate als cannabinoidrezeptorantagonisten
DE602006014973D1 (de) Neuartige cercosporamidderivate
DE602004008447D1 (de) 7-(ä1,4üdioxan-2-yl)-benzothiazol derivative als adenosin-rezeptoren liganden

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1912991

Country of ref document: EP